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Objectives This study compared the quality of life (QOL) of patients with cardiac resynchronization therapy (CRT) and an
implantable cardioverter-defibrillator (ICD) to patients with an ICD only.
Background CRT with ICD is associated with a reduction in heart failure risk among minimally symptomatic patients. It is
unknown whether this improves QOL.
Methods This study uses the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchroni-
zation Therapy) data. The MADIT-CRT enrolled 1,820 patients at 110 centers across 14 countries. Patients had
ischemic cardiomyopathy (New York Heart Association [NYHA] functional class I or II) or nonischemic cardiomy-
opathy (NYHA functional class II only), sinus rhythm, an ejection fraction of 30% or less, and prolonged intraven-
tricular conduction with a QRS duration of 130 ms or more. QOL was evaluated on the 1,699 patients with base-
line and follow-up measures using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Six dimensions
(Physical Limitation, Symptom Stability, Symptom Frequency, Symptom Burden, Quality of Life, and Social Limi-
tations) and 3 summary scores (Total Symptom, Clinical Summary, and Overall Summary) were analyzed.
Results During an average follow-up of 2.4 years, the CRT-ICD group had greater improvement than the ICD-only group
on all KCCQ measures (p  0.05 on each scale). These differences were significant among patients with left
bundle branch block conduction disturbance (n  1,204, p  0.01 on each scale), but not among patients with-
out left bundle branch block (n  494).
Conclusions Compared with patients with ICD only, CRT-ICD is associated with greater improvement in QOL among relatively
asymptomatic patients, specifically among those with left bundle branch conduction disturbance. (J Am Coll
Cardiol 2012;60:1940–4) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.054The MADIT-CRT (Multicenter Automatic Defibrillator
Implantation Trial With Cardiac Resynchronization Ther-
apy) showed the combined cardiac resynchronization ther-
apy (CRT) and implantable cardioverter-defibrillator
(ICD), compared with ICD only, had a 34% reduction in
risk of death from any cause or a nonfatal heart failure event
among patients with mild heart failure (New York Heart
Association [NYHA] functional classes I and II). This
reduction was primarily driven by a 41% reduction in the
risk of heart failure events (1). Moreover, Zareba et al. (2)
and Goldenberg et al. (3) reported that CRT-ICD therapy
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accepted June 19, 2012.was primarily beneficial among those with a left bundle
branch block (LBBB) conduction disturbance.
In this paper, we address whether adding CRT to ICD
comes at the expense of a decrease in quality of life, or
whether it provides an improvement among patients with
mild heart failure (NYHA functional classes I and II). We
assess changes in quality of life among those with and
without LBBB conduction disturbance.
Methods
Detailed information about the MADIT-CRT study de-
sign, randomization, recruitment, and outcome has been
published (1,4). The MADIT-CRT trial enrolled 1,820
patients at 110 centers in 14 countries (1,271 patients in the
United States) from December 22, 2004, through April 23,
2008; the trial was stopped on June 22, 2009. Patients
enrolled in the study had ischemic cardiomyopathy (NYHA
functional class I or II) or nonischemic cardiomyopathy
(NYHA functional class II only), sinus rhythm, an ejection
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conduction with a QRS duration of 130 ms or more.
The analyses presented here were based on 1,699 pa-
tients, which comprise the subset of the original 1,820
patients who had baseline observations and at least 1
additional observation on our outcome variables up to the
close of the study.
Quality-of-life assessment. To assess quality of life, we
used 6 basic scales and 3 summary scales of the Kansas City
Cardiomyopathy Questionnaire (KCCQ) instrument that
comprises heart failure–specific quality-of-life–related mea-
sures (5–11). The 6 basic scales included the Symptom
Stability, Symptom Frequency, Symptom Burden, Physical
Limitation, Quality of Life, and Social Limitation scales.
The 3 summary scales included the Total Symptom, Clin-
ical Summary, and Overall Summary scores. See the Online
Appendix for a discussion of these scales.
Quality-of-life analysis. We used feasible generalized least
squares (12) to estimate models of the KCCQ measures in
which all variables are centered on hospital means, thereby
eliminating hospital fixed effects, and multiplied by het-
eroskedasticity weights to account for the different numbers
of subjects at each hospital.
The data were slightly different in baseline blood pressure
across the arms; therefore, to reduce error variance, we
adjusted analyses for baseline systolic and diastolic blood
pressure levels.
For each KCCQ scale, we estimated 2 models: Model 1
tested the difference in the change from baseline in the
CRT-ICD group compared with the change from baseline
in the ICD-only group on the KCCQ scales across the 4.5
Baseline Characteristics and KCCQ Scores by Treatment Arm andTable 1 Baseline Characteristics and KCCQ Scores by Treatme
All Patients*
ICD-Only
(n  675)
CRT-ICD
(n  1,024)
Characteristics
Age, yrs 64.4 10.6 64.4 10.8
Female, % 24% 25%
Systolic blood pressure 120.8 17.7 123.8 17
Diastolic blood pressure 70.7 10.4 72.3 10.2
NYHA functional class I† 16% 14%
Baseline KCCQ scores‡
Symptom stability 50.3 13.9 50.3 14.6
Symptom frequency 81.6 19.4 81.0 19.7
Symptom burden 82.7 18.0 82.2 18.1
Physical limitation 78.1 20.6 78.8 19.6
Quality of life 66.4 24.4 66.4 23.2
Social limitation 74.1 25.5 75.4 23.8
Total symptom score 82.1 18.0 81.6 18.2
Clinical summary score 80.2 17.8 80.2 17.1
Overall summary score 75.2 19.1 75.6 18.2
Values are mean  SD or %. Data are from patients who had baseline blood pressure measures
significantly different variables between ICD-only and CRT-ICD groups for All Patients, LBBB Patien
the All Patients results. †The percentage for NYHA functional class II classification is 100 minusCRT  cardiac resynchronization therapy; ICD  implantable cardioverter-defibrillator; KCCQ  Kansas
ssociation.years of the study period. Model
2 tested whether the treatment
effect varied across time period
quintiles within the 4.5 years of
the study period: joint tests were
used of the interaction terms be-
tween indicators of the time
quintiles and the indicator of
CRT-ICD group.
LBBB subgroup analyses. We
repeated the analyses of Models
1 and 2 on the LBBB and non-
LBBB subgroups. We investi-
gated whether the differences in
effects were statistically different between the LBBB and
non-LBBB subgroups in Model 1 by testing the interaction
of the LBBB indicator and the CRT-ICD group indicator
using data that included all patients.
Sensitivity analyses. See the Online Appendix for our in-
vestigation of whether date of enrollment, dying or being lost
to follow-up, or the patient switching device during the study
impacted the KCCQ scores differentially across study arms.
Results
Patient characteristics. Table 1 shows baseline character-
istics and baseline KCCQ scores of the study cohort by
treatment arm and LBBB status.
Quality-of-life differences and trends. Figure 1 shows the
estimated difference in effects between the CRT-ICD and
ICD-only groups, and the corresponding 95% confidence
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
ICD  implantable
cardioverter-defibrillator
KCCQ  Kansas City
Cardiomyopathy
Questionnaire
LBBB  left bundle branch
block
NYHA  New York Heart
Association
Statusm and LBBB Status
LBBB Patients Non-LBBB Patients
ICD-Only
(n  482)
CRT-ICD
(n  722)
ICD-Only
(n  192)
CRT-ICD
(n  302)
4.4 10.8 64.1 10.9 64.4 10.3 65.1 10.7
29% 32% 12% 10%
1.1 17.6 123.9 16.6 120.1 18.2 123.5 17.9
0.3 10.4 72.3 10.0 71.5 10.4 72.3 10.6
12% 11% 25% 21%
0.9 13.9 50.7 14.0 48.7 14.0 49.2 16.0
1.8 19.4 82.0 18.8 81.0 19.5 78.8 21.6
3.1 17.7 83.0 17.1 81.7 18.8 80.3 20.2
8.4 20.2 79.7 18.6 77.3 21.7 76.6 21.6
6.1 24.0 66.9 22.5 67.4 25.7 65.4 24.8
4.3 25.6 76.5 22.7 73.6 25.3 72.7 26.1
2.5 17.8 82.5 17.2 81.3 18.4 79.5 20.1
0.5 17.5 81.1 16.4 79.4 18.5 78.1 18.6
5.4 18.7 76.4 17.4 74.9 20.2 73.7 19.8
t least 2 KCCQ measures, including baseline. Systolic and diastolic blood pressures are the only
Non-LBBB Patients. *One individual did not have an indicated LBBB status and is included only in
rted percent for NHYA functional class I. ‡Some scores (at most, 5%) are missing.
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ICD-CRT and Quality of Life in Heart Failure November 6, 2012:1940–4intervals, from Model 1 for each KCCQ measure, adjusted
for baseline systolic and diastolic blood pressure levels. A
positive value means the CRT-ICD group had a larger effect
(i.e., change from baseline) in KCCQ scores than the ICD-
only group. The first panel depicts estimates for the entire
study population. The second panel depicts the estimates
for the LBBB subgroup. The third panel depicts estimates
for the non-LBBB subgroup, which were not significant for
each measure. The interactions between the LBBB indica-
tor and ICD-CRT group indicator, estimated using all
patients, were significantly different between the LBBB and
non-LBBB subgroups for all KCCQ measures (p  0.05)
xcept for the Symptom Severity and Symptom Burden
cales (p  0.91 and p  0.06, respectively).
The analysis of Model 2, using the entire study popula-
ion, resulted in rejecting the hypothesis that the treatment
ffect does not vary by time for each KCCQ measure
significant at the 0.05 level), except for the Physical
imitation, Symptom Frequency, and Symptom Stability
cales, which were not significant. The significant findings
n these joint tests suggested that a difference in effect exists
or at least 1 of the time quintiles. However, we cannot rule
ut that at least 1 time quintile had no difference (the joint
est of the hypothesis that at least 1 parameter was 0 was
nsignificant for each measure—all tests had p values
0.49). The LBBB subgroup analysis of Model 2 resulted
n in the same inferences, but results of Model 2 applied to
he non-LBBB subgroup were not significant for each
Figure 1 Differences in Effect and 95% CIs, for Each KCCQ Me
Differences in effect is defined as the change from baseline for the cardiac resync
from baseline for the ICD-only group. Results are adjusted for baseline systolic an
non-LBBB subgroups; †Up to 5% of patients were omitted due to missing data. CI
left bundle branch block.easure.Figure 2 shows the mean Overall Summary score of the
KCCQ among the LBBB subgroup for each 6-month
period between enrollment and Year 3. Table 2 shows the
sample sizes for each of these time periods by treatment
group. Similar to the preceding analyses, these differences
based on the non-LBBB subgroup were not statistically
significant, whereas those based on the full sample fell in
between.
Discussion
The results of this study provide evidence that CRT-ICD is
associated with better improvement in heart failure–specific
quality of life than ICD-only among minimally symptom-
atic patients. Specifically, better effects were found among
the CRT-ICD group with respect to all KCCQ measures
we evaluated. These findings were statistically evident
among patients with LBBB but not discernible among those
without this conduction disturbance. Evidence suggests that
the difference between groups varies across time since
enrollment, particularly during the first 2 years.
The KCCQ scores range from 0 through 100 points. The
magnitudes of treatment-assignment effects on changes in
the KCCQ measures reported here are on the order of
approximately 1 to 3 points. Spertus et al. (13) found that
differences of 5 points on KCCQ Overall Summary score
correspond to changes in patient heart failure status that
were judged by cardiologists to be small in terms of clinical
changes. Changes in patient clinical heart failure status
ation therapy–implantable cardioverter-defibrillator (CRT-ICD) group minus change
tolic blood pressure levels. *Significantly different effects between the LBBB and
fidence interval; KCCQ  Kansas City Cardiomyopathy Questionnaire; LBBB asure
hroniz
d dias
 conjudged to be large by cardiologists corresponded to changes
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Flynn et al. (14) found a 5-point change in the KCCQ
overall score was associated with a 2.50-ml/kg change in
peak VO2 and a 112-m change in 6-min walking distance;
hey judged these changes to be clinically meaningful. What
s not clear, however, is how patients, rather than cardiol-
gists and researchers, would deem the difference in life
xperiences, rather than clinical indicators, that correspond
o the differences in effects that we observed. This is an
mportant factor for providers assisting patients to attain the
atients’ goals, particularly for patients who value the quality
f their life experiences (15).
There is insufficient previous research on minimally
ymptomatic patients (i.e., research restricted to NYHA
unctional class I and II) to provide a direct comparison for
Figure 2 Average Overall Summary Score (With 95% CI) by Tre
for Every 6 Months From Randomization to 3 Years
Each difference between CRT-ICD and ICD-only groups is statistically significant ex
viations as in Figure 1.
Sample Size by LBBB Type and Treatment Group Across Years in tTable 2 Sample Size by LBBB Type and Treatment Group Acros
Year
All Patients*
ICD-Only CRT-ICD Total ICD-Only
0 675 1,024 1,699 482
0.5 652 998 1,650 464
1 638 985 1,623 453
1.5 535 849 1,384 391
2 421 668 1,089 305
2.5 292 456 748 222
3 196 297 498 151Estimates in Figure 2 are based on the sample sizes reported in the LBBB columns. *One individual did
Abbreviations as in Table 1.ur results. The aforementioned studies by Spertus et al.
13) and Flynn et al. (14) evaluated sicker patient groups
hat include NYHA functional classifications greater than
I. This is true of other studies that evaluate KCCQ
easures as well. For example, Myers et al. (16), Sullivan et
l. (16), Ekman et al. (17), Eurich et al. (6), Heidenreich et
l. (18), and Soto et al. (19), each found associations
etween KCCQ measures and relevant outcomes, but each
ere assessing a sicker patient population (including NHYA
unctional classes III and/or IV). Because the MADIT-
RT patient population is minimally symptomatic, with
aseline KCCQ scores starting in the upper half of the scale
ange, changes in KCCQ measures are expected to be lower
han among patients with worse initial scores (20). Conse-
uently, any quality-of-life improvement is notable, but
nt Status Among LBBB Patients
t baseline and year 3. Sample sizes for each group are shown in Table 2. Abbre-
udy From Randomization (Year 0) Through Year 3ars in the Study From Randomization (Year 0) Through Year 3
LBBB Non-LBBB
CRT-ICD Total ICD-Only CRT-ICD Total
722 1,204 192 302 494
705 1,169 187 293 480
700 1,153 184 285 469
610 1,001 143 239 382
484 789 115 184 299
336 558 70 120 190
221 372 45 76 121atme
cept ahe Sts Yenot have an indicated LBBB status and is included only in the All Patients results.
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ICD-CRT and Quality of Life in Heart Failure November 6, 2012:1940–4additional research is necessary to identify the extent that
the effect sizes found in our study impact the lives of
patients in this population and thereby impact treatment
decisions and satisfaction.
Notwithstanding the need for future research to identify
the importance to patients of the effects identified in this
study, the improvement found across all KCCQ measures
suggests that the clinical benefits of resynchronization
therapy (1), as an adjunct to the ICD, do not come at the
expense of quality of life—a finding that may be reassuring
to patients. Instead, the CRT-ICD is associated with a
greater increase in quality of life than ICD-only among the
minimally symptomatic patients, who might otherwise have
been presumed to not garner a discernible improvement.
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APPENDIX
For supplementary information on the KCCQ scales and the sensitivity
analyses, please see the online version of this paper.
